Okay. Hi, my name is Nora Balas. I am a postdoctoral fellow at the University of Alabama at Birmingham, and I'm excited to attend Ash 2024 on behalf of my colleagues to present our research focusing on the role of Self-rated health as an independent predictor of subsequent mortality among blood or matter transplants survivors who receive who receive BMT for myeloid malignancies.
And we've seen improvement in transplantation strategy and supportive care that have led to an increase in the number of patients who receive BMT. For myeloid malignancy, however, those patients carry a significant burden of late occurring morbidity, placing them at high risk of late mortality. So it is important to understand the role of self-rated health among myeloid malignancies patients.
Self-rated health is a single item measures for an individual's evaluations of their own health, and it's measured by asking the question in general, would you say your health is excellent? Very good. Good, fair or poor? And responses indicating fair or poor at a classified as suboptimal self-rated health. Previous research have demonstrated that self-rated health is an independent predictor of mortality among general and cancer population, and to understand the role of self-rated health among myeloid malignancies patient.
We retrieved our cohort from the BMT Survivor Study. It is a retrospective cohort study includes patients who were transplanted in city of Hope, University of Minnesota and the UAB and they had to have survived two years or more after the transplant. And for this report, we restricted participants to those who received the single BMT for myeloid malignancies and were 18 years or older at a study of participation. In summary, 25% of the myeloid malignancies patients who were treated with BMT reported suboptimal self-rated health.
Factors associated with suboptimal self-rated health included lack of exercise, pain, socioeconomics, low socioeconomic status, severe or life threatening chronic condition, and psychological distress. Moreover, patients who received BMT for myeloid malignancies were a two fold higher hazard of all cause mortality compared to those who reported good self-rated health. So incorporating this single item measures into the clinical workflow for survivors follow up would enhance patients management and, long term outcomes. If we focus on modifiable factors, including pain management, encourage patients to do exercise and, manage their, mental health and like, control or monitor their mental health that could benefit mortality after the transplantation for myeloid malignancies patients.
HealthTree • January 15, 2025